BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has a beta value of 2.88 and has seen 2,772,451 shares traded in the recent trading session. The company, currently valued at $822.03 Million, closed the recent trade at $4.65 per share which meant it lost -$0.3 on the day or -6.43% during that session. The BCRX stock price is -35.27% off its 52-week high price of $6.29 and 70.32% above the 52-week low of $1.38. If we look at the company’s 10-day average daily trading volume, we find that it stood at 9.11 Million shares traded. The 3-month trading volume is 10.87 Million shares.
The consensus among analysts is that BioCryst Pharmaceuticals, Inc. (BCRX) is an Overweight stock at the moment, with a recommendation rating of 2.1. None of the analysts rate the stock as a Sell, while none rate it as Overweight. 3 out of 9 have rated it as a Hold, with 6 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$0.26.
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) trade information
Despite being -6.33% in the red today, the stock has traded in the green over the last five days, with the highest price hit on Monday, Jun 29 when the BCRX stock price touched $5.29-1 or saw a rise of 10.13%. Year-to-date, BioCryst Pharmaceuticals, Inc. shares have moved 37.8%, while the 5-day performance has seen it change 11.34%. Over the past 30 days, the shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) have changed 5.77%. Short interest in the company has seen 20.63 Million shares shorted with days to cover at 1.9.
BioCryst Pharmaceuticals, Inc. (BCRX) estimates and forecasts
Figures show that BioCryst Pharmaceuticals, Inc. shares have underperformed across the wider relevant industry. The company’s shares have gained +59.62% over the past 6 months, with this year growth rate of 1.06%, compared to 11% for the industry. Other than that, the company has, however, increased its growth outlook for the 2020 fiscal year revenue. Growth estimates for the current quarter are 23.5% and 32.4% for the next quarter. Revenue growth from the last financial year stood is estimated to be -40.8%.
9 analysts offering their estimates for the company have set an average revenue estimate of $2.12 Million for the current quarter. 9 have an estimated revenue figure of $5.71 Million for the next quarter concluding in September 01, 2020. Year-ago sales stood $2.02 Million and $2.96 Million respectively for this quarter and the next, and analysts expect sales will grow by 5% for the current quarter and 92.9% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -6.8% over the past 5 years. Earnings growth for 2020 is a modest +4% while over the next 5 years, the company’s earnings are expected to increase by 19.9%.
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)’s Major holders
Insiders own 0.95% of the company shares, while shares held by institutions stand at 90.2% with a share float percentage of 91.07%. Investors are also buoyed by the number of investors in a company, with BioCryst Pharmaceuticals, Inc. having a total of 186 institutions that hold shares in the company. The top two institutional holders are Blackrock Inc. with over 13.4 Million shares worth more than $26.79 Million. As of March 30, 2020, Blackrock Inc. held 7.59% of shares outstanding.
The other major institutional holder is Baker Brothers Advisors, LLC, with the holding of over 10.95 Million shares as of March 30, 2020. The firm’s total holdings are worth over $21.89 Million and represent 6.21% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and Janus Henderson Global Life Sciences Fund. As of March 30, 2020, the former fund manager holds about 2.65% shares in the company for having 4669457 shares of worth $9.34 Million while later fund manager owns 4.01 Million shares of worth $13.82 Million as of December 30, 2019, which makes it owner of about 2.27% of company’s outstanding stock.